Impatience, lack of clarity as clock ticks on AstraZeneca expiry date

0

TORONTO — Impatience and a lack of clarity persisted Thursday over the fate of thousands of doses of the Oxford-AstraZeneca vaccine set to expire in the coming weeks.

Several provinces have stopped giving the COVID-19 shot over concerns of rare, fatal blood clots. Health authorities were still trying to decide whether to resume its use and if using a different vaccine for second shots makes sense.

At the same time, Ottawa is distributing hundreds of thousands of AstraZeneca doses to the provinces, some of which are sitting on soon-to-expire stockpiles.

Justin Bates, head of the Ontario Pharmacists Association, said an announcement that had been expected on Thursday would now likely happen in the coming days. The association, he said, was in confidential discussions with the province about using the AstraZeneca, something he said should be done.

“Absolutely. We have a shared objective with the ministry to ensure that we use, wherever appropriate and feasible, all of the AstraZeneca remaining doses.”

Ontario is banking on a steady increase in vaccinations for its three-phased reopening to start, tentatively in mid-June. Health Minister Christine Elliott indicated on Thursday the province was leaning toward using AstraZeneca for second doses.

“We are waiting for the final recommendations (from experts) on what we should do with the AstraZeneca vaccine,” Elliott said. “Data from the U.K. indicate that any problems with the second shot are far less.”

Federal Health Minister Patty Hajdu said earlier this week the vaccines would not go to waste but Ontario, which has about 31,000 unused doses, is up against a May 31 expiry date. Similarly, Manitoba has also reported having about 7,000 AstraZeneca doses that need to be used before month’s end.

“Provinces and territories are weighing their options very closely in terms of second doses for those people who have received AstraZeneca for a first dose,” Hajdu said.

Bates said it would take a concerted effort to get the shots in arms, if approved, involving reaching out patients to schedule an appointment. They would also need to provide informed consent around dosage intervals and relative risks, which he said were far outweighed by the potential benefits.

“We’re just waiting for direction,” Bates said. “We can move quickly.”

Dr. Irfan Dhalla, an internal medicine specialist in Toronto, said people should be able to make their own choice as to whether get AstraZeneca, either as a first of second dose, or wait for another brand known as an mRNA vaccine.

“If somebody has to wait several weeks to get an mRNA vaccine and could have an AstraZeneca vaccine today, it would be very reasonable for an individual … to prefer to have an AstraZeneca vaccine today,” Dhalla said earlier in the week.

“Similarly, it’s very reasonable for people who have already had one dose to want to have their second dose now rather than wait 16 weeks, and then have a second dose with an mRNA vaccine.”

More than 2.1 million people have had AstraZeneca. Health authorities said there were about two-dozen confirmed cases of vaccine-induced thrombotic thrombocytopenia, or VITT, the rare but serious blood-clotting disorder.

The National Advisory Committee on Immunization, known as NACI, was still awaiting data from a mixing-and-matching study underway in Britain.

Dr. Joss Reimer, medical lead of Manitoba’s vaccine task force, couldn’t say how many doses might not be used. Nothing prevents doctors or pharmacists from giving the shots as long as manufacturer and Health Canada rules are followed, she said.

“There are unique circumstances where people may benefit from an earlier dose,” Reimer said. “Clinicians do have the ability to do an individual assessment.”

-With files from Holly McKenzie-Sutter in Toronto

Colin Perkel, The Canadian Press